PALO ALTO, Calif.--(BUSINESS WIRE)--CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced results of two studies evaluating the role of the Corus® CAD gene expression test in clinical decision-making for the evaluation of patients with suspected obstructive coronary artery disease (CAD). Results were presented last week at the Quality of Care and Outcomes Research (QCOR) 2012 Scientific Session in Atlanta, Ga., and the Society of General Internal Medicine (SGIM) 35th Annual Meeting in Orlando, Fla.
